T-cell receptor (TCR) recognizing human metapneumovirus (hMPV) fusion (F) protein-derived peptides presented by major histocompatibility complex (MHC) (TCR)

The T-cell receptor (TCR) recognizing human metapneumovirus (hMPV) fusion (F) protein-derived peptides presented by the major histocompatibility complex (MHC) is a specialized immune protein complex essential for identifying and eliminating hMPV-infected cells (Sun et al., 2021, Nature Communications). hMPV is a ubiquitous paramyxovirus that causes significant respiratory disease, especially in vulnerable populations such as the immunocompromised (Williams et al., 2004, NEJM). These TCRs are typically found on CD8+ T cells and recognize specific viral epitopes, most notably the F161–169 peptide (KLGAGIGIA) when presented by HLA-A*02:01 (Steensels et al., 2022, Journal of Virology). Recognition of this peptide-MHC complex triggers T-cell activation, leading to the secretion of granzymes, perforins, and cytokines like IFN-gamma to clear the infection. In clinical settings, these TCRs are being investigated as targets for adoptive immunotherapy, where T cells are engineered to express high-affinity TCRs to provide rapid immunity to patients with life-threatening infections (de Graaf et al., 2016, Journal of Clinical Investigation). This therapeutic strategy aims to restore viral control in patients with weakened immune systems, though it requires careful monitoring for off-target effects and cytokine-related toxicities.

Other names

hMPV-specific T-cell receptorTCR recognizing hMPV F peptidesHuman metapneumovirus-specific TCRhMPV F-specific TCR

Engineered or endogenous T-cell receptors bind specifically to hMPV fusion protein peptides presented by MHC molecules on the surface of infected cells, triggering T-cell activation, cytokine release, and direct lysis of the target cell.